[1] Winship IR, Dursun SM, Baker GB, etal. An Overview of Animal Models Related to Schizophrenia
[J]. Can J Psychiatry. 2019, 64(1):5-17.

[2] Loots E, Goossens E, Vanwesemael T, et al. Interventions to Improve Medication Adherence in Patients with Schizophrenia or Bipolar Disorders: A Systematic Review and Meta-Analysis
[J]. Int J Environ Res Public Health. 2021, 18(19):10213.

[3] Rhee TG, Rosenheck RA. Does improvement in symptoms and quality of life in chronic schizophrenia reduce family caregiver burden
[J]? Psychiatry Res. 2019, 271:402-404.

[4] Kimura H, Kanahara N, Iyo M. Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity
[J]. Behav Brain Res. 2021, 403:113126.

[5] Yang L, Qi X. Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function
[J]. Pak J Med Sci. 2021, 37(3):646-650.

[6] Yoshimura Y, Takeda T, Kishi Y, et al. Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study
[J]. Int Clin Psychopharmacol. 2018, 33(3):147-154.

[7] Barry CL, McGinty EE, Pescosolido BA, et al. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness
[J]. Psychiatr Serv. 2014, 65(10):1269-72.

[8] Chopko TC, Lindsley CW. Classics in Chemical Neuroscience: Risperidone
[J]. ACS ChemNeurosci. 2018, 9(7):1520-1529.

[9] Kahn René S.,Silverman Bernard L., Di Petrillo Lauren, GrahamChristine,JiangYing,YinJiani,SimmonsAdam,BhupathiVasudev,YuBei,YagodaSergey,HopkinsonCraig,McDonnellDavid.A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
[J]. Schizophrenia Research. 2021: 32-38.

[10] Correll Christoph U, Newcomer John W, Silverman Bernard, Di Petrillo Lauren, Graham Christine, Jiang Ying, Du Yang chun, Simmons Adam, Hopkinson Craig, Mc Donnell David, Kahn René S.Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.The American journal of psychiatry .
[J] .2020,(12):112-119.

[11] Morrison AP, Pyle M, Byrne R, et al. Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT
[J]. Health Technol Assess. 2021, 25(4):1-124.

[12] Güneş M, Camkurt MA, Bulut M, et al. Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment
[J]. Clin Psychopharmacol Neurosci. 2016, 14(4):345-350.

[13] Lähteenvuo M, Tiihonen J. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
[J]. Drugs. 2021, 81(11):1273-1284.

[14] Greenwood J, Acharya RB, Marcellus V, et al. Lumateperone: A Novel Antipsychotic for Schizophrenia
[J]. Ann Pharmacother. 2021, 55(1):98-104.

[15] Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis
[J]. Lancet. 2022, 399(10327):824-836.